Wuxi AppTec reports 33.7% jump in first-half 2026 net profit as US revenue rises to 22.28 billion yuan
AI Market Summary
Wuxi AppTec reported first-half 2026 net profit up 33.7%, materially above consensus, with US revenue rising 56.5% and comprising ~77% of total sales. Results signal strong demand for outsourced pharma R&D/manufacturing tied to obesity and diabetes drug commercialization. However, ongoing US regulatory scrutiny remains an overhang, creating headline risk even as US business growth highlights the firm's entrenched role in global biopharma supply chains.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.43%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Wuxi AppTec said net profit attributable to owners rose 33.7% year on year to 11.08 billion yuan in the first half of 2026, beating analysts’ expectations. Revenue in the United States increased to 22.28 billion yuan, up from 14.24 billion yuan a year earlier. The company said it benefited from commercial progress across clients’ drug programmes, driving strong growth in revenue, profit and cash flow. Despite US regulatory scrutiny, its US business continued to expand, underscoring its role in global pharmaceutical supply chains.
